China Healthcare:Further execution in 19provinces

类别:行业研究 机构:国信证券(香港)金融控股有限公司 研究员:Jason Siu 日期:2017-10-12

On 20 Sept 2017, Economics Information Daily (经济参考报) reported that fouradditional provinces, namely Jiangxi, Yunnan, Gansu and Shanxi, had included 36high-priced medicines into their provincial reimbursement drug list (RDL). Thesedrug names are the same as those shortlisted by the national government on 19July. Including these four provinces, it should now have over 19 provinces to addthese 36 drugs into their RDL.

    The article highlighted that, as imported drugs can now be included into RDL at thebigger expense of selling prices, this makes the cheaper local-made medicines tobe less competitive in the market. In addition, the national government will try toimplement this bigger price cut mechanism on high-priced medicines in exchangefor their volume jump in most provinces. Coupled with good surveillance of drugcost spending, Chinese government aims to curb the over-usage of these highpriceddrugs, including monoclonal antibodies.

    The same source also cited that, with the drug cost reimbursement amount fixedby the government post negotiation, it would be unlikely to see bigger selling pricefluctuations to hospitals for these high-priced medicines. Whereby these drugs areusually (1) to treat critical and rare diseases such as cancers; and (2) hard toproduce with good barriers of entry.

    As we flagged in our 12 Sept 2017 note, we see these drugs with clinicalimportance would likely have their sales volume rebound (in particular to foreigndrugs), at the expense of their selling prices, similar to the case with GSK’sTenofovir Disoproxil Fumarate (Viread?). Consistent with national governmentpolicy, it aims to provide Chinese masses accessible to cheaper quality medicinewith good efficacies. We expect this will increase the likelihood for many provincesto introduce further price cut on domestic drugs for critical illness, such as anticancerand stroke medicines.

    Stock impact: This will dampen the sentiment of local drug-maker sector in theshort-term, despite of potential sales volume rebound for these import drugs fromsacrificing their selling prices. Same as we mentioned, we do not surprise to seefurther tough policy (such as price cut) on domestic high-priced drugs such aschemical drugs and monoclonal antibodies for anti-cancer therapy. Aside fromChina Medical System’s (867.HK, NR) XinHuoSu (新活素?; Nesiritide?), we see thismay also affect HK-listed CSPC (1093.HK, NR)’s future pricing on its Bortezomib forinjection (硼替佐米) as a first-to-market generic drug, which is currently on thathigh-priced drug list. Note that, CSPC has applied for production approval fromCFDA, likely to be on sales in the next 12 to 16 months.



三安光电 持有 -- 研报
东山精密 持有 -- 研报
卓翼科技 持有 -- 研报
京东方A 持有 -- 研报
风华高科 持有 -- 研报
久立特材 持有 -- 研报
天成自控 持有 35.00 研报
东安动力 持有 15.00 研报
福田汽车 持有 4.60 研报
上汽集团 持有 38.50 研报
宇通客车 持有 30.50 研报


分众传媒 0 0 研报
捷成股份 1.05 0.81 研报
新华都 0.65 0.36 研报
金一文化 0 0 研报
合肥百货 0.90 0.68 研报
苏宁云商 0.70 0.56 研报
潮宏基 0.81 0.94 研报
武汉中商 0.36 0.30 研报
飞亚达A 0.42 0.41 研报
红旗连锁 0 0.87 研报
天虹股份 0.86 0.76 研报


清新环境 40 持有 持有
先导智能 34 持有 中性
伊利股份 30 持有 持有
桐昆股份 30 持有 买入
中兴通讯 30 持有 持有
保利地产 29 持有 买入
万科A 29 持有 买入
海大集团 29 持有 持有
贵州茅台 28 持有 持有
中国国旅 28 持有 持有
启迪桑德 28 持有 持有
汇川技术 27 持有 持有
聚光科技 27 持有 买入
通威股份 26 持有 持有
烽火通信 26 持有 持有
分众传媒 26 持有 持有
先导智能 25 持有 中性


电子信息 974 115 269
机械行业 670 85 240
化工行业 588 68 204
食品行业 584 34 171
酿酒行业 548 19 119
农林牧渔 545 38 250
生物制药 530 69 206
建筑建材 523 52 287
汽车制造 523 48 131
房地产 506 49 169
交通运输 471 48 150
金融行业 467 36 166
煤炭行业 453 34 110
环保行业 401 24 87
电子器件 367 68 88
服装鞋类 343 31 125
酒店旅游 340 27 158